Benchmark Reiterates Speculative Buy on ImmunoPrecise Antibodies, Maintains $7 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Robert Wasserman has reiterated a Speculative Buy on ImmunoPrecise Antibodies (NASDAQ:IPA) and maintained a $7 price target.
July 11, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst has reiterated a Speculative Buy on ImmunoPrecise Antibodies and maintained a $7 price target.
The reiteration of a Speculative Buy rating and maintenance of a $7 price target by Benchmark analyst Robert Wasserman indicates a positive outlook for ImmunoPrecise Antibodies. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100